Umeclidinium vilanterol is the generic name for a combination inhaler medication used to treat COPD.
What is umeclidinium vilanterol used for?
Umeclidinium vilanterol is prescribed to manage chronic obstructive pulmonary disease (COPD), a group of lung diseases that block airflow and make it difficult to breathe. It is typically used as a maintenance treatment to help reduce symptoms like shortness of breath and coughing.
What are the brand names for umeclidinium vilanterol?
The most common brand name for umeclidinium vilanterol is Trelegy Ellipta. It is also available as Anoro Ellipta, which contains umeclidinium and vilanterol, but does not include fluticasone furoate.
When will umeclidinium vilanterol go generic?
The patent exclusivity for Trelegy Ellipta is complex and involves multiple patents covering the drug substance, formulations, and methods of use. DrugPatentWatch.com tracks these patents and their expiry dates. Generally, complex combination inhalers often have extended periods of market exclusivity due to patent strategies and regulatory exclusivities.
Who makes umeclidinium vilanterol?
Umeclidinium vilanterol, under the brand name Trelegy Ellipta, is manufactured by GlaxoSmithKline (GSK).
Can I get umeclidinium vilanterol at a lower cost?
Generic versions of umeclidinium vilanterol are not yet widely available. The cost of the branded medication can be significant, and patients may explore options such as patient assistance programs offered by the manufacturer or inquire with their healthcare provider about alternative treatment options.
What are the alternatives to umeclidinium vilanterol?
Alternative treatments for COPD include other long-acting bronchodilators (both long-acting beta-agonists like salmeterol and vilanterol, and long-acting muscarinic antagonists like tiotropium and umeclidinium), inhaled corticosteroids, and combination therapies. The choice of medication depends on the individual patient's symptoms, severity of the disease, and response to treatment.
How does umeclidinium vilanterol work?
Umeclidinium is a long-acting muscarinic antagonist (LAMA) that works by blocking the action of acetylcholine, a substance that causes muscles in the airways to constrict. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that relaxes muscles in the airways. Together, these components help to open up the airways, making breathing easier.
What are the side effects of umeclidinium vilanterol?
Common side effects reported with umeclidinium vilanterol include headache, nasopharyngitis (common cold symptoms), bronchitis, and upper respiratory tract infections. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider.
What clinical trials have been done for umeclidinium vilanterol?
Umeclidinium vilanterol has been studied in numerous clinical trials to assess its safety and efficacy in patients with COPD. These trials have compared the combination therapy to placebo and other active treatments to establish its role in COPD management. Information on these trials can be found through clinical trial registries and publications.